T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
DON'T BUY

Pfizer Inc(PFE)

Sep 22, 2005
Drug stars such as Pfizer (PFE-N) Merck (MRK-N), etc. are attractively valued but are clearly out of favour. They have great long term track records and are in strong financial positions, however, there is a lack of predictability regarding the science. Doesn't like the cash flow dynamics where they spend billions up front with no sure win ahead. Litigation risks.
Photo of James Cole, BA, CFAJames Cole, BA, CFA
Owned
Unlock Rating
$25.25

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 21, 2005
Still likes and is a believer in this company. His model price is 50% above the current price, but doesn't know when that value will be recognized.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.31

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 20, 2005
No advantage to be in this stock. The whole drug area has changed in the last few years and they are not as strong as they once were. The market seems to be moving more to generics.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$25.40

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 07, 2005
His model price is $37.65, an 46% differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.51

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 31, 2005
Very cheap on the numbers, but they have a patent issue on their largest drug, Lippitor. If they lost Lippitor, you would be looking at a stock below $20 overnight. There's a lot of risk in the name.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$25.48

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2005
Have recently added this to his fund. Good free cash flow, strong balance sheet. There is some risk right now with their Lipitor drug. A group in India is making a generic version.
Photo of Peter HofstraPeter Hofstra
Owned
Unlock Rating
$25.36

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Aug 12, 2005
Have done a lot of restructuring. Will cut their costs which will help. Part of the problem in the pharmaceutical industry has been the poor leadership in the FDA. A cheap stock and you're getting paid a 3.5% yield. Trades at a very low multiple.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.16

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 09, 2005
It's in a big trading range of $25/29. Don't let it go below the low of $24. Hopefully it will break up through the trend line. You should be in this for at least 2 years.
Photo of Bill CarriganBill CarriganUnlock Rating
$26.70

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 04, 2005
Has a model price of $38.43.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.60

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 20, 2005
They beat the numbers today. Numbers are pretty low. They are taking costs out. The problems with these stocks, which are all innovation dependent, is essentially depletion through generics.
Photo of Danny TomkaDanny Tomka
No
Unlock Rating
$27.06

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 19, 2005
Prefers the US health care stocks as they are much larger and much more seasoned. The big pharma has been a very difficult area. This one has been under a bit of a cloud, but it's cheap on an earnings basis.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$27.38

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 13, 2005
Growth rate went from 30% three years ago to almost low single digits or flat. Not performing well. The group is in the early stages of a turn around, but would be more inclined to buy the company that has flourished through this period. Would prefer Abbott Labs (ABT-N).
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$27.23

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 06, 2005
The whole area has been beaten up and is very interesting. The big pharmas have a big challenge as the pipelines are a little bit bare. Would rather own companies that are suppliers to the pharmas, such as IMS Health (RX-N). (He doesn't follow big caps.)
Photo of Phil TallerPhil Taller
No
Unlock Rating
$26.77

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 02, 2005
RE:Call options Jan/07. Not particularily expensive as it has not been a volatile stock. Not a bad way to play the stock if you are bullish on the company. The company has a very good dividend, so call option are less than the put options quite often. (His play on this is through the Vipers (VHT-A).)
Photo of Richard CroftRichard Croft
No
Unlock Rating
$27.50

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 25, 2005
Got in on the Celebrex recall. This company has developed some fantastic drugs. Pharmaceutical stocks in the US have been absolutely decimated. Dirt cheap. 3.5% didvidend yield while you wait for a recovery. Generates a ton of free cash flow. Merck & Company (MRK-N) are in the same way.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
Owned
Unlock Rating
$27.03

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 661 to 675 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like